Core Viewpoint - China Tongfu (01763) has achieved domestic large-scale production of the radioactive nuclide Gallium-68 precursor, Germanium-68, marking a significant advancement in the country's nuclear medicine capabilities [1] Group 1: Company Developments - Atomic High-Tech Co., Ltd. has successfully utilized a 30MeV proton cyclotron to produce Germanium-68, meeting commercial product standards required by Europe and the United States [1] - This achievement indicates that China now possesses a stable and independent production capacity for Germanium-68, which is crucial for the precise diagnosis and treatment of cancer patients [1] Group 2: Industry Implications - Germanium-68 is the parent nuclide of Gallium-68, which decays to produce Gallium-68 used in PET imaging for tumor diagnosis, providing essential support for clinical cancer treatment [1] - There are currently 13 Gallium-68 drugs in clinical trials in China, with several already approved for use abroad, highlighting a broad market potential for Germanium-68 in both domestic and international markets [1] - The company plans to continue focusing on the nuclear medicine sector, increasing investment in the research and development of nuclide drugs to support the advancement of precision medicine and enhance public health [1]
中国同辐：原子高科首次实现放射性核素锗-68的国产规模化制备